Recurrent Thrombosis in a Patient With Behçet Disease Successfully Treated With Infliximab

Vascular involvement is a major cause of morbidity and mortality in Behçet’s disease (BD), particularly in male patients. Immunosuppressive therapy is the mainstay of treatment, but recurrent thrombotic events may occur despite conventional immunosuppression. We report a 53‐year‐old male with a history of BD complicated by recurrent pulmonary and deep venous thrombosis despite treatment with cyclophosphamide, azathioprine, and warfarin. He presented with left lower extremity pain and swelling. Doppler ultrasonography revealed acute and chronic deep venous thrombosis. Thoracoabdominal computed tomography angiography demonstrated a near‐complete filling defect consistent with pulmonary embolism without abdominal thrombosis and signs of other kinds of systemic vasculitis. High‐dose corticosteroids were initiated, and infliximab (5 mg/kg at Weeks 0, 2, and 6) was added to previous azathioprine and colchicine therapy. Warfarin was continued after consultation with the cardiovascular surgery team. Within 2 weeks, the patient showed marked clinical improvement, reduced inflammatory markers, and regression of the thrombus on follow‐up imaging. This case underscores the importance of reassessing inflammatory disease control and early consideration of biologic therapy, such as infliximab, especially in refractory cases, to prevent further vascular damage and improve outcomes.